U.S. Government Plans to Collect DNA from Detained Immigrants
By Caitlin Dickerson,
The New York Times
| 10. 02. 2019
The Trump administration is moving to collect DNA samples from hundreds of thousands of people booked into federal immigration custody each year and to enter the results into a national criminal database, an immense expansion of the use of technology to enforce the nation’s immigration laws.
Senior officials at the Department of Homeland Security said Wednesday that the Justice Department was developing a federal regulation that would give immigration officers the authority to collect DNA in detention facilities across the country that are currently holding more than 40,000 people.
The move would funnel thousands of new records to the F.B.I., whose extensive DNA database has been limited mainly to genetic markers collected from people who have been arrested, charged or convicted in connection with serious crimes.
There have long been calls to collect immigrant DNA records to help identify criminals who have previously been in immigration custody but may not otherwise be known to the authorities. Congress passed a law authorizing a broad collection of DNA data in 2005, but at the time an exemption was put in place to... see more
Related Articles
By Sarah Zhang, The Atlantic | 06.22.2022
Photo by ANIRUDH on Unsplash
In October 2019, Jordan Janz became the first person in the world to receive an experimental therapy for cystinosis, a rare genetic disease. The treatment was physically grueling. Doctors extracted blood stem cells from Janz’s...
By Ian Sample , The Guardian | 06.22.2022
More than half the UK backs the idea of rewriting the DNA of human embryos to prevent severe or life-threatening diseases, according to a survey.
Commissioned by the Progress Educational Trust (PET), a fertility and genomics charity, the Ipsos poll...
By Fiorella Valdesolo, WSJ Magazine | 06.08.2022
“Where is the we?” It’s the question that was the driving force for Vida Delrahim and Ronit Menashe when they created WeNatal, a new brand of prenatal supplements that aims to be more inclusive. In the process of trying...
By Michael Le Page, New Scientist | 06.16.2022
CRISPR gene-editing trials for treating sickle cell disease and beta thalassaemia are being extended to include children aged under 12 after the therapies proved successful in ongoing trials involving people aged between 12 and 35. The aim is to treat...